Frontiers in Cellular and Infection Microbiology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2021-12-07 啦啦啦kevin

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肠道菌群
经验分享：07 Dec 2021
Article accepted for publication.
06 Dec 2021
Review of Review Editor 3 finalized.
Review of Review Editor 4 finalized.
05 Dec 2021
Corresponding Author Jianning Zhao submitted manuscript.
Corresponding Author Jianning Zhao re-submitted manuscript.
You posted new comments.
You posted new comments.
23 Nov 2021
Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2.
Interactive review forum activated.
15 Nov 2021
Review of Reviewer is finalized.
29 Oct 2021
Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor.
17 Oct 2021
Corresponding Author Jianning Zhao submitted manuscript.

332 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2024-07-09 ms5000000182160519 来自北京

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：幽门螺杆菌;细胞死亡
经验分享：中了回来报恩，感谢论坛各位
Date Updates
08 Jul 2024
(15:51:17) Article accepted for publication.
05 Jul 2024
(17:48:49) Review of Review Editor 2 finalized.
(17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript.
04 Jul 2024
(15:03:48) Interactive review forum activated automatically.
29 Jun 2024
(15:03:44) Review of Review Editor 3 is finalized.
13 Apr 2024
(06:15:44) Corresponding Author Fafeng Cheng submitted manuscript.

17 0

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2024-05-14 行云流水fjsl 来自福建省

编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！

36 0

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2023-01-27 Asmallriver 来自湖南省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：传染病
经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何

87 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2022-06-08 kongmin

12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验

72 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2023-08-25 ms8000000563552859 来自江苏省

审稿速度:1.0 | 投稿命中率:95.0
经验分享：wu

0 0

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2023-08-24 ms6000000127821627 来自澳大利亚

审稿速度:3.0
偏重的研究方向：肠道菌群
经验分享：5月20投稿
8月2日第一个审稿人意见返回
8月5号第二个审稿人意见返回并finalized
8月11号交互评审
8月19号提交回复及修改稿
8月20 进入review finalized阶段
8月24 收到接收邮件

67 0

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2021-06-24 123971fdm77暂无昵称

proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。

702 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2023-05-09 ms7000000507856696 来自江苏省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤
经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。

92 0

[GetPortalCommentsPageByObjectIdResponse(id=1077867, encodeId=38ae10e78674f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肠道菌群 经验分享：07 Dec 2021 Article accepted for publication. 06 Dec 2021 Review of Review Editor 3 finalized. Review of Review Editor 4 finalized. 05 Dec 2021 Corresponding Author Jianning Zhao submitted manuscript. Corresponding Author Jianning Zhao re-submitted manuscript. You posted new comments. You posted new comments. 23 Nov 2021 Guest Associate Editor Nar Singh Chauhan reactivated the review of Review Editor 2. Interactive review forum activated. 15 Nov 2021 Review of Reviewer is finalized. 29 Oct 2021 Associate Editor Nar Singh Chauhan assigned Nar Singh Chauhan as the new Guest Associate Editor. 17 Oct 2021 Corresponding Author Jianning Zhao submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e035516833, createdName=啦啦啦kevin, createdTime=Tue Dec 07 21:24:48 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2214081, encodeId=e1e72214081cb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：幽门螺杆菌;细胞死亡 经验分享：中了回来报恩，感谢论坛各位 Date Updates 08 Jul 2024 (15:51:17) Article accepted for publication. 05 Jul 2024 (17:48:49) Review of Review Editor 2 finalized. (17:40:09) Corresponding Author Fafeng Cheng re-submitted manuscript. 04 Jul 2024 (15:03:48) Interactive review forum activated automatically. 29 Jun 2024 (15:03:44) Review of Review Editor 3 is finalized. 13 Apr 2024 (06:15:44) Corresponding Author Fafeng Cheng submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=101c9075350, createdName=ms5000000182160519, createdTime=Tue Jul 09 14:39:58 CST 2024, time=2024-07-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2204703, encodeId=ff3f2204e0383, content=编辑在Initial Validation阶段要求“请提供作者组不同成员参与撰写稿件的证据。”可以是投稿前组员间互通邮件、聊天应用信息或者是已发表评论的手稿注释稿。大家有遇到这种情况吗？请大佬们指导！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue May 14 19:21:34 CST 2024, time=2024-05-14, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2111587, encodeId=4cf0211158ecb, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：传染病 经验分享：中过一次了，感觉比较容易中，这几天又投了一个，凌晨12点投的，早上5点起床看已经分配编辑了。不知道结果如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqz1JJib9x1sPvL72jJHNRTac4co6mxuJib3hahuxVLVVRXks28xP5d5Hibl7cBuuYkfU6S16HK4dEtA/132, createdBy=7add2279854, createdName=Asmallriver, createdTime=Fri Jan 27 09:03:54 CST 2023, time=2023-01-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1225265, encodeId=c8501225265cb, content=12，May，2022，投稿，到现在一个月了，没动静，着急啊，哪位分享下经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0c71620219, createdName=kongmin, createdTime=Wed Jun 08 21:04:50 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154494, encodeId=1366215449421, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：wu , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd226572749, createdName=ms8000000563552859, createdTime=Fri Aug 25 09:05:10 CST 2023, time=2023-08-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154340, encodeId=ccbb2154340a3, content=审稿速度:3.0 偏重的研究方向：肠道菌群 经验分享：5月20投稿 8月2日第一个审稿人意见返回 8月5号第二个审稿人意见返回并finalized 8月11号交互评审 8月19号提交回复及修改稿 8月20 进入review finalized阶段 8月24 收到接收邮件 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88258387646, createdName=ms6000000127821627, createdTime=Thu Aug 24 08:57:42 CST 2023, time=2023-08-24, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=976645, encodeId=e8ee9e66456b, content=proof后2个多月都还没在线发表，比我后接收一个月的都在线了，关键是这还是是OA期刊，搞不懂。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=702, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8542420944, createdName=123971fdm77暂无昵称, createdTime=Thu Jun 24 23:13:47 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131251, encodeId=e0b021312512a, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：本人作为客座编辑在frontiers cellular infection microbiology（IF6.073）期刊开了一个主题为“New Insights into the Role of Tumor Microbial Microenvironment in Tumor Immunotherapy”的专刊，现在已经开放投稿。如果大家有主题相关的稿件，欢迎大家积极投稿。投稿完成后，我会第一时间处理稿件并择优选择你们投稿时推荐的审稿专家，提升稿件处理流程和接收速度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 22:50:16 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115177, encodeId=041b21151e790, content=偏重的研究方向：传染病;微生物学 经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gCTJBEQ5byrcLVTrgfDXfla5W6WWlUKBXwXrNf9ibibsIW1nPGLgd2rMDBcSbSyznMzBuRwEPMbyhx1iazzMKXAxw/132, createdBy=653e2361163, createdName=lqby321, createdTime=Fri Feb 17 23:55:26 CST 2023, time=2023-02-17, status=1, ipAttribution=山东省)]

2023-02-17 lqby321 来自山东省

偏重的研究方向：传染病;微生物学
经验分享：杂志编辑非常负责，审稿人意见很中肯，个人觉得该杂志文章质量不错。

88 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务